Literature DB >> 33164997

Inflammatory endotypes of CRSwNP and responses to COVID-19.

Ming Wang1,2, Chengshuo Wang1, Luo Zhang1,2,3.   

Abstract

PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly become a great public health hazard globally. Nasal epithelial cells are an important site for SARS-CoV-2 infection and replication. The purpose of this review is to summarize recent findings on the endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) and the potential impact of SARS-CoV-2 infection. RECENT
FINDINGS: Endotypes of CRSwNP are characterized by type 1, type 2 and type 3 inflammation according to patterns of inflammatory cells and the cytokines expressed in nasal tissue. Nasal epithelial cells show the highest expression of angiotensin-converting enzyme 2 (ACE2), the receptor for attachment and entry of SARS-CoV-2 into host cells, among all investigated cells in the respiratory tree. SARS-CoV-2 infection likely leads to increased activation of T-helper-1 (Th1) cell responses. Recent studies further suggest that ACE2 may be upregulated by type 1 and downregulated by type 2 inflammatory cytokines in nasal epithelial cells.
SUMMARY: Expression of ACE2 in nasal epithelial cells is influenced by inflammatory endotypes of CRSwNP. Type 1 inflammation in nasal tissue may increase the risk of SARS-CoV-2 infection by upregulating ACE2 expression. However, clinical association between CRSwNP and COVID-19 is still unclear.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33164997     DOI: 10.1097/ACI.0000000000000700

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  7 in total

Review 1. 

Authors:  Oliver Pfaar; Ludger Klimek; Eckard Hamelmann; Jörg Kleine-Tebbe; Christian Taube; Martin Wagenmann; Thomas Werfel; Randolf Brehler; Natalija Novak; Norbert K Mülleneisen; Sven Becker; Margitta Worm
Journal:  Allergo J       Date:  2021-08-13

Review 2.  SARS-CoV-2 Infection of Airway Epithelial Cells.

Authors:  Gwanghui Ryu; Hyun-Woo Shin
Journal:  Immune Netw       Date:  2021-03-02       Impact factor: 6.303

3.  COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA).

Authors:  Oliver Pfaar; Ludger Klimek; Eckard Hamelmann; Jörg Kleine-Tebbe; Christian Taube; Martin Wagenmann; Thomas Werfel; Randolf Brehler; Natalija Novak; Norbert Mülleneisen; Sven Becker; Margitta Worm
Journal:  Allergol Select       Date:  2021-04-01

Review 4.  SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.

Authors:  Evgenii Gusev; Alexey Sarapultsev; Liliya Solomatina; Valeriy Chereshnev
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

5.  Pathological consequences of chronic olfactory inflammation on neurite morphology of olfactory bulb projection neurons.

Authors:  Brandon J LaFever; Yuka Imamura Kawasawa; Ayako Ito; Fumiaki Imamura
Journal:  Brain Behav Immun Health       Date:  2022-03-18

Review 6.  SARS-CoV-2 Infection (COVID-19) and Rhinologic Manifestation: Narrative Review.

Authors:  Seung Hoon Lee; Min Young Seo
Journal:  J Pers Med       Date:  2022-07-28

7.  Differential susceptibility to SARS-CoV-2 in the normal nasal mucosa and in chronic sinusitis.

Authors:  Zhili Zhang; Haoran Peng; Ju Lai; Liangliang Jiang; Liefu Wang; Shengkai Jin; Kai Fan; Zimu Zhang; Chuanliang Zhao; Dan Deng; Ping Zhao; Zhengliang Gao; Shaoqing Yu
Journal:  Eur J Immunol       Date:  2022-05-14       Impact factor: 6.688

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.